open access

Vol 79, No 3 (2011)
EDUKACJA. Zmniejszmy ciężar przewlekłej obturacyjnej choroby płuc (cz. II)
Published online: 2011-04-21
Submitted: 2013-02-22
Get Citation

New drugs in chronic obstructive pulmonary disease

Ryszarda Chazan
Pneumonol Alergol Pol 2011;79(3):232-238.

open access

Vol 79, No 3 (2011)
EDUKACJA. Zmniejszmy ciężar przewlekłej obturacyjnej choroby płuc (cz. II)
Published online: 2011-04-21
Submitted: 2013-02-22

Abstract

Inhaled bronchodilators such as beta2-agonists and muscarinic antagonists help to prevent and control symptoms in COPD patients, reduce the frequency and severity of exacerbations, improve health status and exercise tolerance and have an acceptable safety profile. For patients with moderate to severe COPD combining bronchodilators from different classes long acting beta2-agonists or long acting muscarinic antagonists (LABA/LAMA) are recommended. Indacaterol with 24 hours duration and fast onset of bronchodilation is the first once daily dosing LABA. Indacaterol used alone or in combination with LAMA may be advantageous through simplification of treatment regimens as well as improvement the efficacy. As COPD progresses and patient has repeated exacerbations triple therapy LABA/LAMA/ICS may be required. The addition of PDE4 inhibitor (roflumilast) to LABA or LAMA in patients with severe COPD, improves lung function and reduces exacerbation frequency. The reduction in exacerbation frequency is similar to that seen in the studies on bronchodilators and inhaled corticosteroids therapy. PDE4 inhibitors have been shown to play a role in severe COPD and they are effective particularly in combination with other pharmacological agents. Based on the results of studies combining different classes of the drugs seems to be an important step towards the goal of optimal control for COPD patients.
Pneumonol. Alergol. Pol. 2011; 79, 3: 232-238

Abstract

Inhaled bronchodilators such as beta2-agonists and muscarinic antagonists help to prevent and control symptoms in COPD patients, reduce the frequency and severity of exacerbations, improve health status and exercise tolerance and have an acceptable safety profile. For patients with moderate to severe COPD combining bronchodilators from different classes long acting beta2-agonists or long acting muscarinic antagonists (LABA/LAMA) are recommended. Indacaterol with 24 hours duration and fast onset of bronchodilation is the first once daily dosing LABA. Indacaterol used alone or in combination with LAMA may be advantageous through simplification of treatment regimens as well as improvement the efficacy. As COPD progresses and patient has repeated exacerbations triple therapy LABA/LAMA/ICS may be required. The addition of PDE4 inhibitor (roflumilast) to LABA or LAMA in patients with severe COPD, improves lung function and reduces exacerbation frequency. The reduction in exacerbation frequency is similar to that seen in the studies on bronchodilators and inhaled corticosteroids therapy. PDE4 inhibitors have been shown to play a role in severe COPD and they are effective particularly in combination with other pharmacological agents. Based on the results of studies combining different classes of the drugs seems to be an important step towards the goal of optimal control for COPD patients.
Pneumonol. Alergol. Pol. 2011; 79, 3: 232-238
Get Citation

Keywords

COPD; LABA; LAMA; ICS; PDE4 inhibitors

About this article
Title

New drugs in chronic obstructive pulmonary disease

Journal

Advances in Respiratory Medicine

Issue

Vol 79, No 3 (2011)

Pages

232-238

Published online

2011-04-21

Bibliographic record

Pneumonol Alergol Pol 2011;79(3):232-238.

Keywords

COPD
LABA
LAMA
ICS
PDE4 inhibitors

Authors

Ryszarda Chazan

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl